NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
6.12
-1.22 (-16.62%)
At close: May 12, 2025, 4:00 PM
6.01
-0.11 (-1.80%)
After-hours: May 12, 2025, 4:18 PM EDT

Company Description

NeOnc Technologies Holdings, Inc., a clinical-stage life sciences company, focuses on the development and commercialization of central nervous system therapeutics designed to overcome the blood-brain barrier.

The company’s NEO drug development platform produces a portfolio of novel drug candidates and delivery methods with patent protections.

Its NEO100-01 and NEO100-02 therapeutics are in Phase II, and the NEO100-03 and NEO212 therapeutics are in Phase I clinical trials, advancing under FDA Fast-Track and Investigational New Drug status.

NeOnc Technologies Holdings, Inc. was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.

The company was founded in 2008 and is based in Westlake Village, California.

NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings logo
Country United States
Founded 2008
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Thomas Chen

Contact Details

Address:
Two Dole Drive
Westlake Village, California 91362
United States
Phone 310-663-7831
Website neonctech.com

Stock Details

Ticker Symbol NTHI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001979414
Employer ID 92-1954864
SIC Code 2834

Key Executives

Name Position
Dr. Thomas C. Chen M.D., Ph.D. Founder, Chief Executive Officer, Chief Scientific Officer and Director
Keithly A. Garnett Chief Financial Officer and Director
Patrick Walters CPA Chief Operating Officer
Amir Farrokh Heshmatpour President, Executive Chairman and Secretary

Latest SEC Filings

Date Type Title
May 9, 2025 10-Q Quarterly Report
May 6, 2025 EFFECT Notice of Effectiveness
May 6, 2025 424B5 Filing
Apr 29, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Apr 25, 2025 SCHEDULE 13D Filing
Apr 11, 2025 D Notice of Exempt Offering of Securities
Apr 11, 2025 8-K Current Report
Apr 1, 2025 8-K Current Report
Apr 1, 2025 8-K Current Report
Mar 27, 2025 8-K Current Report